



CYTOO's MyoScreen™ chosen by DAIICHI SANKYO to discover new drugs in muscle diseases

October 28th, 2015, Grenoble, France- CYTOO announces today that Daiichi Sankyo Company Limited, a Japanese pharmaceutical manufacturer with global presence, has selected CYTOO *in vitro* muscle platform MyoScreen™ to develop a novel cell-based assay and screen drug candidates on a key mechanism involved in several muscular diseases.

MyoScreen™ is a high throughput and high content screening platform that enables the identification and characterization of new compounds that affect muscle hypertrophy, contractility, metabolism and muscular diseases. The system thus meets the broad requirements of the pharmaceutical, nutraceutical and animal health industries aiming ultimately to discover new active ingredients.

Dr. Luc Selig, CEO of CYTOO commented: *“Just a few months after announcing the commercial launch of MyoScreen™, we are proud that Daiichi Sankyo has chosen our platform to identify compounds targeting musculoskeletal diseases. This agreement is a further validation of the value of this unique and innovative drug discovery tool, and follows the signature of several agreements with leaders in the animal health, nutraceuticals and pharmaceutical industries.”*

The human body has more than 600 muscles that provide the power for us to stand and move around. Muscle is an essential tissue affected by numerous factors such as loss of muscle mass associated with ageing (sarcopenia) or certain medications (cachexia) while neuromuscular diseases such as myopathies (Duchenne muscular dystrophy), muscle weakness (myasthenia), amyotrophic lateral sclerosis and spinal muscular atrophy directly impact an individual's motor abilities.

Financial terms of this agreement are not disclosed.

###

About CYTOO

Created in 2008, CYTOO is a biotechnology company specialized in the development of physiologically-relevant cellular models and assays for High Content Screening (HCS). The company has developed its own models of human striated muscle (MyoScreen™) and skin (EpiScreen™, FibroScreen™) available to the pharmaceutical, dermato-cosmetic, nutraceutical, food processing and animal health sectors for screening of biologically active compounds. Independently, the enterprise has engaged in its own drug discovery business committed to treating muscle wasting and Duchenne muscular dystrophy. CYTOO has offices in Grenoble, Paris and the United States.

About MyoScreen™

MyoScreen™, first-in-class physiological human skeletal muscle *in vitro* model for drug screening, compatible with High Content Screening, is based on fully mature human skeletal muscle (from human donors). This model displays an increased maturity which correlates with a better detection of potential hypertrophic compounds to counteract sarcopenia, cachexia and increase muscle mass. MyoScreen™ can be used to develop disease models for metabolic and neuromuscular disorders drug discovery programs. The multiplexed image analysis opens up new avenues for the classification of drugs' mechanism of action. To learn more about CYTOO, please visit: www.cytoo.com.

Press contact Alizé RP:

Florence Portejoie

fportejoie@alizerp.com

Phone : + 33 (0) 1 44 54 36 64

Cell: + 33 (0) 6 47 38 90 04